Rakesh Kumar

This study shows that the Bri2 BRICHOS domain inhibits α-synuclein oligomer formation and toxicity by suppressing secondary nucleation and binding oligomers, suggesting its potential as a therapeutic target for Parkinson's disease.

This study identifies two distinct α-synuclein fibril polymorphs with different structural and functional properties linked to prion-like behavior in Parkinson's disease.

This study investigates how the size of α-synuclein fibril seeds affects their amplification, cellular uptake, and toxicity, revealing distinct mechanisms for small and large seeds.

This study shows that α-synuclein undergoes liquid-liquid phase separation, which transitions to solid amyloid fibrils, contributing to Parkinson's disease pathogenesis.